DOCSLIB.ORG

The Tyrosine Kinase Regulator Cbl Enhances the Ubiquitination and Degradation of the Platelet-Derived Growth Factor Receptor ␣

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Tyrosine Kinase Regulator Cbl Enhances the Ubiquitination and Degradation of the Platelet-Derived Growth Factor Receptor ␣ Proc. Natl. Acad. Sci. USA Vol. 95, pp. 7927–7932, July 1998 Biochemistry The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor a SACHIKO MIYAKE*, MARK L. LUPHER,JR.*, BRIAN DRUKER†, AND HAMID BAND*‡ *Lymphocyte Biology Section, Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115; and †Division of Heamatology and Medical Oncology, Oregon Health Sciences University, Portland, OR 97201 Communicated by K. Frank Austen, Harvard Medical School, Boston, MA, May 6, 1998 (received for review March 10, 1998) ABSTRACT The Cbl protooncogene product has emerged rapidly phosphorylated on tyrosine upon stimulation of cells as a negative regulator of receptor and nonreceptor tyrosine through a number of receptor tyrosine kinases as well as kinases. We recently demonstrated that oncogenic Cbl mu- receptors linked to nonreceptor tyrosine kinases (5–8). Nota- tants upregulate the endogenous tyrosine kinase signaling bly, Cbl is either constitutively (e.g., Src-family kinases) or machinery when expressed in the NIH 3T3 cells, and identified inducibly (e.g., EGFR, PDGFRa,orSykyZAP70 family) the platelet-derived growth factor receptor-a (PDGFRa)as associated with tyrosine kinases themselves (5–8, 12–16). A one of the tyrosine kinases targeted by these oncogenes. These critical determinant of the inducible association of Cbl with findings suggested a role for the normal Cbl protein in tyrosine kinases was identified recently. A phosphotyrosine- negative regulation of the PDGFRa. However, the mechanism binding (PTB) domain within the N-terminal transforming of such negative regulation remained to be determined. Here region of Cbl, corresponding to sequences retained in the v-cbl we show that overexpression of the wild-type Cbl enhances the oncogene, interacts directly with a specific phosphopeptide ligand-induced ubiquitination of the PDGFRa. Concomi- motif on tyrosine kinases to mediate a phosphorylation- tantly, the PDGFRa in Cbl-overexpressing cells undergoes a dependent association between Cbl and protein tyrosine ki- faster ligand-induced degradation compared with that in the nases (14, 15). In certain cases, such as the EGFR and control cells. These results identify a role for Cbl in the PDGFRa, a second indirect mechanism of association is regulation of ligand-induced ubiquitination and degradation provided by the Grb2 adaptor protein, which binds to the of receptor tyrosine kinases and suggest one potential mech- proline-rich region of Cbl via its SH3 domains and to auto- anism for evolutionarily conserved negative regulatory influ- phosphorylated receptors via its SH2 domain (10, 17, 18). ence of Cbl on tyrosine kinases. Notably, the N-terminal PTB domain-containing region (Cbl-N) and an adjacent RING finger domain are the only two Tyrosine kinases provide a universal mode of signal transmis- elements of Cbl highly conserved during evolution (5–8). sion in response to extracellular cues that regulate cell prolif- Indeed, Drosophila Cbl is exclusively composed of these two eration and differentiation. Uncontrolled activation of ty- regions, but nevertheless interacts with the EGFR (10). rosine kinases is implicated in proliferation of cancerous cells, The first evidence for the role of Cbl in negative regulation and their deficiencies result in pathological conditions such as of tyrosine kinase signaling pathways was provided by studies developmental abnormalities and immunodeficiencies (1). of vulval development in C. elegans, a process that requires Tight regulation of tyrosine kinase cascades is therefore LET-23 receptor tyrosine kinase, a homologue of the mam- critical to elicit an appropriate type and level of response to malian EGFR (9). A gene identified as a negative regulator of external stimuli. signaling downstream of the LET-23 receptor, suppressor of Negative regulation of tyrosine kinase-mediated signaling is lineage defect 1 (sli-1), encoded a Cbl homologue, SLI-1. achieved through a number of distinct biochemical mecha- Importantly, loss-of-function mutations identified in SLI-1 nisms. Cellular phosphotyrosine phosphatases provide one corresponded to either premature termination or a missense mechanism to reverse tyrosine kinase signals by removal of the mutation in the conserved Cbl-N homology region. In the phosphate moiety from phosphotyrosine (2). Another mech- Drosophila eye, a functional EGFR homologue is critical for anism to regulate tyrosine kinase signaling is through the the development of the R7 photoreceptor cell and functions removal of receptors, such as epidermal growth factor receptor through a Rasymitogen-activated protein kinase pathway anal- (EGFR) and platelet-derived growth factor receptor ogous to the mammalian EGFR. The recently cloned Dro- (PDGFR), from the cell surface via ligand-induced clathrin sophila Cbl homologue (D-Cbl) was shown to bind to Dro- coat-mediated endocytosis (3, 4). A potent and evolutionarily sophila and mammalian EGFRs and, when expressed as a conserved mechanism to regulate enzyme functions is through transgene under control of a sevenless enhancer, induced the direct interactions with regulatory proteins. However, tyrosine severe reduction in the development of the R7 photoreceptor, kinase regulatory proteins have not been previously identified. providing further evidence for a negative regulatory role of Cbl Recent biochemical studies in mammalian cells (5–8) and in receptor tyrosine kinase signaling (10). independent genetic studies in Caenorhabditis elegans and In mammalian systems, Cbl overexpression in NIH 3T3 cells Drosophila have identified the protooncogene product Cbl as correlated with decreased autophosphorylation of the EGFR a negative regulator of tyrosine kinases (9, 10). and lower JAK-STAT phosphorylation; conversely, higher Cbl was first identified as the cellular homologue of a viral EGFR autophosphorylation was observed in cells expressing oncogene v-cbl, which induces pre-B lymphomas and myeloid lower levels of Cbl as a consequence of antisense Cbl trans- leukemias in mice (11). A large number of studies have now fection (19). Cbl overexpression in the rat basophilic leukemia established that Cbl, a cytoplasmic 120 kDa polypeptide, is Abbreviations: PDGF, platelet-derived growth factor; PDGFR, plate- The publication costs of this article were defrayed in part by page charge let-derived growth factor receptor; EGFR, epidermal growth factor receptor; PTB, phosphotyrosine binding; HRP, horseradish peroxi- payment. This article must therefore be hereby marked ‘‘advertisement’’ in dase; HA, hemagglutinin. accordance with 18 U.S.C. §1734 solely to indicate this fact. ‡To whom reprint requests should be addressed at: Smith Building, © 1998 by The National Academy of Sciences 0027-8424y98y957927-6$2.00y0 Room 538C, 75 Francis Street, Boston, MA 02115. e-mail:hband@ PNAS is available online at http:yywww.pnas.org. rics.bwh.harvard.edu. 7927 7928 Biochemistry: Miyake et al. Proc. Natl. Acad. Sci. USA 95 (1998) cell line RBL-2H3 was shown to decrease the autophosphor- containing 20 mM Hepes buffer solution (pH 7.35) and then ylation and kinase activity of Syk that is induced on Fc«R1 incubated in the same buffer with sulfo-N-hydroxysulfosuccin- stimulation, and mast cell degranulation was severely impaired imide (NHS)-biotin (Pierce) for 15 min at 4°C. After washing, (20). The in vivo negative regulatory phosphorylation site the cells were incubated in a-MEM containing 1 mgyml BSA pY292 was identified as the Cbl PTB domain-binding site on (tissue culture grade; Sigma) with or without PDGF for 15 min ZAP-70 (16). NIH 3T3 cells expressing oncogenic forms of Cbl at 4°C. The cells were washed, incubated at 37°C in a-MEM for revealed a hyperphosphorylation of the PDGF receptor a the indicated times, and lysates were prepared as described (PDGFRa) and an up-regulation of signaling downstream of above. Anti-PDGFRa immunoprecipitates of these lysates this receptor (14). Similarly, NIH 3T3 cells expressing onco- were blotted with avidin-HRP conjugate (Vector Laborato- genic forms of Cbl showed increased autophosphorylation and ries) followed by enhanced chemiluminescence, as described kinase activity of a transfected human EGFR, both under above. Densitometry was carried out by using the Hewlett– serum-starved and EGF-stimulated conditions (21). Appar- Packard ScanJet 4C and Scion Images for Windows software. ently, the effect of oncogenic mutants of Cbl on PDGFRa and Densitometric data were expressed as arbitrary units. EGFR reflects a reversal of the negative regulatory role of wild-type Cbl. RESULTS AND DISCUSSION Together, these studies strongly support a role for Cbl as a negative regulator of diverse tyrosine kinases. However, the Cbl Enhances the Ligand-Induced Ubiquitination of mechanism whereby Cbl negatively regulates tyrosine kinases PDGFRa. Our earlier studies demonstrated that the PDGFRa has not been elucidated. Here we demonstrate that Cbl was hyperactive in NIH 3T3 cells expressing various oncogenic promotes ubiquitination and ligand-induced degradation of mutants of Cbl when compared with cells expressing wild-type the receptor tyrosine kinase PDGFRa, suggesting one mech- Cbl, and led us to suggest that normal Cbl functions as a anism for the negative regulatory action of Cbl on tyrosine negative regulator of PDGFRa signaling (14). In these earlier kinases. studies, we noted that the kinetics
Load more

Recommended publications
  • Tyrosine Kinase – Role and Significance in Cancer
    Int. J. Med. Sci. 2004 1(2): 101-115 101 International Journal of Medical Sciences ISSN 1449-1907 www.medsci.org 2004 1(2):101-115 ©2004 Ivyspring International Publisher. All rights reserved Review Tyrosine kinase – Role and significance in Cancer Received: 2004.3.30 Accepted: 2004.5.15 Manash K. Paul and Anup K. Mukhopadhyay Published:2004.6.01 Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Sector-67, S.A.S Nagar, Mohali, Punjab, India-160062 Abstract Tyrosine kinases are important mediators of the signaling cascade, determining key roles in diverse biological processes like growth, differentiation, metabolism and apoptosis in response to external and internal stimuli. Recent advances have implicated the role of tyrosine kinases in the pathophysiology of cancer. Though their activity is tightly regulated in normal cells, they may acquire transforming functions due to mutation(s), overexpression and autocrine paracrine stimulation, leading to malignancy. Constitutive oncogenic activation in cancer cells can be blocked by selective tyrosine kinase inhibitors and thus considered as a promising approach for innovative genome based therapeutics. The modes of oncogenic activation and the different approaches for tyrosine kinase inhibition, like small molecule inhibitors, monoclonal antibodies, heat shock proteins, immunoconjugates, antisense and peptide drugs are reviewed in light of the important molecules. As angiogenesis is a major event in cancer growth and proliferation, tyrosine kinase inhibitors as a target for anti-angiogenesis can be aptly applied as a new mode of cancer therapy. The review concludes with a discussion on the application of modern techniques and knowledge of the kinome as means to gear up the tyrosine kinase drug discovery process.
    [Show full text]
  • Erbb3 Is Involved in Activation of Phosphatidylinositol 3-Kinase by Epidermal Growth Factor STEPHEN P
    MOLECULAR AND CELLULAR BIOLOGY, June 1994, p. 3550-3558 Vol. 14, No. 6 0270-7306/94/$04.00+0 Copyright C 1994, American Society for Microbiology ErbB3 Is Involved in Activation of Phosphatidylinositol 3-Kinase by Epidermal Growth Factor STEPHEN P. SOLTOFF,l* KERMIT L. CARRAWAY III,1 S. A. PRIGENT,2 W. G. GULLICK,2 AND LEWIS C. CANTLEY' Division of Signal Transduction, Department ofMedicine, Beth Israel Hospital, Boston, Massachusetts 02115,1 and Molecular Oncology Laboratory, ICRF Oncology Group, Hammersmith Hospital, London W12 OHS, United Kingdom2 Received 11 October 1993/Returned for modification 11 November 1993/Accepted 24 February 1994 Conflicting results concerning the ability of the epidermal growth factor (EGF) receptor to associate with and/or activate phosphatidylinositol (Ptdlns) 3-kinase have been published. Despite the ability of EGF to stimulate the production of Ptdlns 3-kinase products and to cause the appearance of PtdIns 3-kinase activity in antiphosphotyrosine immunoprecipitates in several cell lines, we did not detect EGF-stimulated Ptdlns 3-kinase activity in anti-EGF receptor immunoprecipitates. This result is consistent with the lack of a phosphorylated Tyr-X-X-Met motif, the p85 Src homology 2 (SH2) domain recognition sequence, in this receptor sequence. The EGF receptor homolog, ErbB2 protein, also lacks this motif. However, the ErbB3 protein has seven repeats of the Tyr-X-X-Met motif in the carboxy-terminal unique domain. Here we show that in A431 cells, which express both the EGF receptor and ErbB3, Ptdlns 3-kinase coprecipitates with the ErbB3 protein (pl80eR3) in response to EGF. p180B3 is also shown to be tyrosine phosphorylated in response to EGF.
    [Show full text]
  • The Erbb Receptor Tyrosine Family As Signal Integrators
    Endocrine-Related Cancer (2001) 8 151–159 The ErbB receptor tyrosine family as signal integrators N E Hynes, K Horsch, M A Olayioye and A Badache Friedrich Miescher Institute, PO Box 2543, CH-4002 Basel, Switzerland (Requests for offprints should be addressed to N E Hynes, Friedrich Miescher Institute, R-1066.206, Maulbeerstrasse 66, CH-4058 Basel, Switzerland. Email: [email protected]) (M A Olayioye is now at The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Victoria 3050, Australia) Abstract ErbB receptor tyrosine kinases (RTKs) and their ligands have important roles in normal development and in human cancer. Among the ErbB receptors only ErbB2 has no direct ligand; however, ErbB2 acts as a co-receptor for the other family members, promoting high affinity ligand binding and enhancement of ligand-induced biological responses. These characteristics demonstrate the central role of ErbB2 in the receptor family, which likely explains why it is involved in the development of many human malignancies, including breast cancer. ErbB RTKs also function as signal integrators, cross-regulating different classes of membrane receptors including receptors of the cytokine family. Cross-regulation of ErbB RTKs and cytokines receptors represents another mechanism for controlling and enhancing tumor cell proliferation. Endocrine-Related Cancer (2001) 8 151–159 Introduction The EGF-related peptide growth factors The epidermal growth factor (EGF) or ErbB family of type ErbB receptors are activated by ligands, known as the I receptor tyrosine kinases (RTKs) has four members:EGF EGF-related peptide growth factors (reviewed in Peles & receptor, also termed ErbB1/HER1, ErbB2/Neu/HER2, Yarden 1993, Riese & Stern 1998).
    [Show full text]
  • Intratumoral Heterogeneity of Receptor Tyrosine Kinases EGFR and PDGFRA Amplification in Glioblastoma Defines Subpopulations with Distinct Growth Factor Response
    Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response Nicholas J. Szerlipa, Alicia Pedrazab, Debyani Chakravartyb, Mohammad Azimc, Jeremy McGuirec, Yuqiang Fangd, Tatsuya Ozawae, Eric C. Hollande,f,g,h, Jason T. Hused,h, Suresh Jhanward, Margaret A. Levershac, Tom Mikkelseni, and Cameron W. Brennanb,f,h,1 aDepartment of Neurosurgery, Wayne State University Medical School, Detroit, MI 48201; bHuman Oncology and Pathogenesis Program, cMolecular Cytogenetic Core Laboratory, dDepartment of Pathology, eCancer Biology and Genetics Program, fDepartment of Neurosurgery, gDepartment of Surgery, and hBrain Tumor Center, Memorial Sloan-Kettering Cancer Center, New York, NY 10065; and iDepartments of Neurology and Neurosurgery, Henry Ford Health System, Detroit, MI 48202 Edited by Webster K. Cavenee, Ludwig Institute, University of California at San Diego, La Jolla, CA, and approved December 29, 2011 (received for review August 29, 2011) Glioblastoma (GBM) is distinguished by a high degree of intra- demonstrated in GBM and has been shown to mediate resistance tumoral heterogeneity, which extends to the pattern of expression to single-RTK inhibition through “RTK switching” in cell lines and amplification of receptor tyrosine kinases (RTKs). Although (11). Although such RTK coactivation has been measured at the most GBMs harbor RTK amplifications, clinical trials of small-mole- protein level, its significance in maintaining tumor cell sub- cule inhibitors targeting individual RTKs have been disappointing to populations has not been established. date. Activation of multiple RTKs within individual GBMs provides We have previously reported prominent PDGFR activation by a theoretical mechanism of resistance; however, the spectrum of platelet-derived growth factor beta (PDGFB) ligand in GBMs EGFR MET fi functional RTK dependence among tumor cell subpopulations in with or ampli cation (12).
    [Show full text]
  • Ephrin-A Binding and Epha Receptor Expression Delineate the Matrix Compartment of the Striatum
    The Journal of Neuroscience, June 15, 1999, 19(12):4962–4971 Ephrin-A Binding and EphA Receptor Expression Delineate the Matrix Compartment of the Striatum L. Scott Janis, Robert M. Cassidy, and Lawrence F. Kromer Department of Cell Biology and Interdisciplinary Program in Neuroscience, Georgetown University Medical Center, Washington, DC 20007 The striatum integrates limbic and neocortical inputs to regulate matrix neurons. In situ hybridization for EphA RTKs reveals that sensorimotor and psychomotor behaviors. This function is de- the two different ligand binding patterns strictly match pendent on the segregation of striatal projection neurons into the mRNA expression patterns of EphA4 and EphA7. anatomical and functional components, such as the striosome Ligand–receptor binding assays indicate that ephrin-A1 and and matrix compartments. In the present study the association ephrin-A4 selectively bind EphA4 but not EphA7 in the lysates of ephrin-A cell surface ligands and EphA receptor tyrosine of striatal tissue. Conversely, ephrin-A2, ephrin-A3, and kinases (RTKs) with the organization of these compartments ephrin-A5 bind EphA7 but not EphA4. These observations im- was determined in postnatal rats. Ephrin-A1 and ephrin-A4 plicate selective interactions between ephrin-A molecules and selectively bind to EphA receptors on neurons restricted to the EphA RTKs as potential mechanisms for regulating the com- matrix compartment. Binding is absent from the striosomes, partmental organization of the striatum. which were identified by m-opioid
    [Show full text]
  • PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD)
    PDGFRB FISH PRODUCT DATASHEET Proprietary Name: PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD) Established Name: PDGFRB FISH for Gleevec in MDS/MPD INTENDED USE Humanitarian Device. Authorized by Federal law for use in the qualitative detection of PDGFRB gene rearrangement in patients with MDS/MPD. The effectiveness of this device for this use has not been demonstrated. Caution: Federal Law restricts this device to sale by or on the order of a licensed practitioner. PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD) is an in vitro diagnostic test intended for the qualitative detection of PDGFRB gene rearrangement from fresh bone marrow samples of patients with MDS/MPD with a high index of suspicion based on karyotyping showing a 5q31~33 anomaly. The PDGFRB FISH assay is indicated as an aid in the selection of MDS/MPD patients for whom Gleevec® (imatinib mesylate) treatment is being considered. This assay is for professional use only and is to be performed at a single laboratory site. SUMMARY AND EXPLANATION OF THE TEST The PDGFRB FISH assay detects rearrangement of the PDGFRB locus at chromosome 5q31~33 in adult patients with myelodysplastic syndrome/myeloproliferative disease (MDS/MPD). The PDGFRB gene encodes a cell surface receptor tyrosine kinase that upon activation stimulates mesenchymal cell division. Rearrangement of PDGFRB has been demonstrated by classical cytogenetic analysis in an exceedingly small fraction of MDS/MPD patients (~1%), usually cases with a clinical phenotype of chronic myelomonocytic leukemia (CMML). In particular, these patients harbor a t(5:12)(q31;p12) translocation involving the PDGFRB and ETV6 genes.
    [Show full text]
  • Targeting the Function of the HER2 Oncogene in Human Cancer Therapeutics
    Oncogene (2007) 26, 6577–6592 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc REVIEW Targeting the function of the HER2 oncogene in human cancer therapeutics MM Moasser Department of Medicine, Comprehensive Cancer Center, University of California, San Francisco, CA, USA The year 2007 marks exactly two decades since human HER3 (erbB3) and HER4 (erbB4). The importance of epidermal growth factor receptor-2 (HER2) was func- HER2 in cancer was realized in the early 1980s when a tionally implicated in the pathogenesis of human breast mutationally activated form of its rodent homolog neu cancer (Slamon et al., 1987). This finding established the was identified in a search for oncogenes in a carcinogen- HER2 oncogene hypothesis for the development of some induced rat tumorigenesis model(Shih et al., 1981). Its human cancers. An abundance of experimental evidence human homologue, HER2 was simultaneously cloned compiled over the past two decades now solidly supports and found to be amplified in a breast cancer cell line the HER2 oncogene hypothesis. A direct consequence (King et al., 1985). The relevance of HER2 to human of this hypothesis was the promise that inhibitors of cancer was established when it was discovered that oncogenic HER2 would be highly effective treatments for approximately 25–30% of breast cancers have amplifi- HER2-driven cancers. This treatment hypothesis has led cation and overexpression of HER2 and these cancers to the development and widespread use of anti-HER2 have worse biologic behavior and prognosis (Slamon antibodies (trastuzumab) in clinical management resulting et al., 1989).
    [Show full text]
  • Genetic Testing for Germline Mutations of the RET Proto-Oncogene AHS - M2078
    Corporate Medical Policy Genetic Testing for Germline Mutations of the RET Proto-Oncogene AHS - M2078 File Name: genetic_testing_for_germline_mutations_of_the_ret_proto-oncogene Origination: 1/2019 Last CAP Review 3/2021 Next CAP Review: 3/2022 Last Review: 3/2021 Description of Procedure or Service The RET (rearranged during transfection) proto-oncogene encodes a transmembrane receptor tyrosine kinase (Takahashi, Ritz, & Cooper, 1985) that regulates a complex network of signal transduction pathways during development, survival, proliferation, differentiation, and migration of the enteric nervous system progenitor cells (Hedayati, Zarif Yeganeh, Sheikholeslami, & Afsari, 2016). Disruption of RET signaling by mutation, gene rearrangement, overexpression or transcriptional up-regulation of the RET gene is implicated in several human cancers (Plaza-Menacho, Mologni, & McDonald, 2014), most commonly thyroid, but also chronic myelomonocytic leukemia, acute myeloid leukemia, and lung, breast, pancreatic, and colon cancers (Gordon et al., 2018). Mutation of the RET gene in a germline cell results in an autosomal dominant hereditary cancer syndrome, multiple endocrine neoplasia type 2 (MEN2) characterized by medullary thyroid carcinoma (MTC), pheochromocytoma (PHEO), and primary parathyroid hyperplasia (PPTH). (Figlioli, Landi, Romei, Elisei, & Gemignani, 2013). This policy covers genetic testing for germline variants in the RET gene. For information on testing of tumors for RET variants to guide chemotherapy. Related Policies M2109 Molecular Panel Testing of Cancers to Identify Targeted Therapy M2030 Testing for Targeted Therapy of Non-Small-Cell Lung Cancer M2108 Molecular Markers in Fine Needle Aspirates of the Thyroid. ***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.
    [Show full text]
  • KIT Somatic Mutations and Immunohistochemical Expression in Canine Oral Melanoma
    animals Article KIT Somatic Mutations and Immunohistochemical Expression in Canine Oral Melanoma Ginevra Brocca 1,* , Beatrice Poncina 1, Alessandro Sammarco 1,2 , Laura Cavicchioli 1 and Massimo Castagnaro 1 1 Department of Comparative Biomedicine and Food Science, University of Padua, Legnaro, 35020 Padua, Italy; [email protected] (B.P.); [email protected] (A.S.); [email protected] (L.C.); [email protected] (M.C.) 2 Department of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA * Correspondence: [email protected] Received: 9 November 2020; Accepted: 7 December 2020; Published: 10 December 2020 Simple Summary: Malignant melanomas arising from mucosal sites are very aggressive neoplastic entities which affect both humans and dogs. The family of tyrosine kinase receptors has been increasingly studied in humans for this type of neoplasm, especially the gene coding for the proto-oncogene KIT, and tyrosine kinase inhibitors are actually available as treatment. However, KIT alteration status in canine oral melanoma still lacks characterization. In this study, we investigated the mutational status and the tissue expression of KIT through DNA sequencing and immunohistochemical analysis, respectively. A homogeneous cohort of 14 canine oral melanomas has been collected, and while tissue expression of the protein was detected, no mutations were identifiable, most likely attributing the dysregulation of this oncogene to a more complex pattern of genomic aberration. Abstract: Canine oral melanoma (COM) is an aggressive neoplasm with a low response to therapies, sharing similarities with human mucosal melanomas. In the latter, significant alterations of the proto-oncogene KIT have been shown, while in COMs only its exon 11 has been adequately investigated.
    [Show full text]
  • Activating Mutations in HER2: Neu Opportunities and Neu Challenges
    VIEWS IN THE SPOTLIGHT Activating Mutations in HER2 : Neu Opportunities and Neu Challenges Britta Weigelt and Jorge S. Reis-Filho Summary: Twenty-fi ve years after the publication of seminal studies showing that HER2 gene amplifi cation and protein overexpression are oncogenic in breast cancer, Bose and colleagues report on the identifi cation of acti- vating HER2 somatic mutations that, albeit rare, may determine the response of breast cancer cells to anti-HER2 agents. These results herald a new era for the potential use of existing HER2-targeted agents for the treatment of patients with HER2 -mutant breast cancer. Cancer Discov; 3(2); 145–7. ©2012 AACR. See related article by Bose et al ., p. 224 (7) . The HER2 ( ERBB2 ) proto-oncogene is amplifi ed and its HER2 agents ( Fig. 1 ). Taken together, these tantalizing fi ndings product overexpressed in approximately 15% to 20% of breast provide a rationale for the development of HER2 sequencing- cancers ( 1 ). The characterization of the impact of HER2 gene directed clinical trials assessing the treatment of patients with amplifi cation and overexpression on the behavior of breast HER2 -mutant breast cancer using HER2-targeted agents. cancers resulted in the development of targeted therapies for Massively parallel sequencing studies have revealed that the the treatment of patients with HER2-positive breast cancer repertoire of somatic mutations in breast cancers is complex, ( 2 ). Furthermore, fl uorescence in situ hybridization (FISH), with a limited number of genes that are highly recurrently chromogenic in situ hybridization (CISH), and immunohis- mutated, even fewer highly recurrent hotspot mutations, and tochemical assays for HER2 have been introduced as predic- a plethora of genes affected by mutations in a small minor- tive biomarkers to determine which patients may benefi t ity (i.e., 1%–3%) of breast cancers ( 8 ).
    [Show full text]
  • Eph Receptor Signalling: from Catalytic to Non-Catalytic Functions
    Oncogene (2019) 38:6567–6584 https://doi.org/10.1038/s41388-019-0931-2 REVIEW ARTICLE Eph receptor signalling: from catalytic to non-catalytic functions 1,2 1,2 3 1,2 1,2 Lung-Yu Liang ● Onisha Patel ● Peter W. Janes ● James M. Murphy ● Isabelle S. Lucet Received: 20 March 2019 / Revised: 23 July 2019 / Accepted: 24 July 2019 / Published online: 12 August 2019 © The Author(s) 2019. This article is published with open access Abstract Eph receptors, the largest subfamily of receptor tyrosine kinases, are linked with proliferative disease, such as cancer, as a result of their deregulated expression or mutation. Unlike other tyrosine kinases that have been clinically targeted, the development of therapeutics against Eph receptors remains at a relatively early stage. The major reason is the limited understanding on the Eph receptor regulatory mechanisms at a molecular level. The complexity in understanding Eph signalling in cells arises due to following reasons: (1) Eph receptors comprise 14 members, two of which are pseudokinases, EphA10 and EphB6, with relatively uncharacterised function; (2) activation of Eph receptors results in dimerisation, oligomerisation and formation of clustered signalling centres at the plasma membrane, which can comprise different combinations of Eph receptors, leading to diverse downstream signalling outputs; (3) the non-catalytic functions of Eph receptors have been overlooked. This review provides a structural perspective of the intricate molecular mechanisms that 1234567890();,: 1234567890();,: drive Eph receptor signalling, and investigates the contribution of intra- and inter-molecular interactions between Eph receptors intracellular domains and their major binding partners. We focus on the non-catalytic functions of Eph receptors with relevance to cancer, which are further substantiated by exploring the role of the two pseudokinase Eph receptors, EphA10 and EphB6.
    [Show full text]
  • 5.01.534 Multiple Receptor Tyrosine Kinase Inhibitors
    PHARMACY POLICY – 5.01.534 Multiple Receptor Tyrosine Kinase Inhibitors Effective Date: Aug. 1, 2021 RELATED MEDICAL POLICIES: Last Revised: July 9, 2021 5.01.517 Use of Vascular Endothelial Growth Factor Receptor (VEGF) Inhibitors and Replaces: N/A Other Angiogenesis Inhibitors in Oncology Patients 5.01.518 BCR-ABL Kinase Inhibitors 5.01.544 Prostate Cancer Targeted Therapies 5.01.589 BRAF and MEK Inhibitors 5.01.603 Epidermal Growth Factor Receptor (EGFR) Inhibitors Select a hyperlink below to be directed to that section. POLICY CRITERIA | CODING | RELATED INFORMATION EVIDENCE REVIEW | REFERENCES | HISTORY ∞ Clicking this icon returns you to the hyperlinks menu above. Introduction An enzyme is a chemical messenger. Tyrosine kinases are enzymes within cells. They serve as on/off switches for many of the cells’ functions. One of their most important roles is to help send signals telling a cell to grow. If there is a genetic change that leaves the switch permanently on, cells grow without stopping and tumors form. Multiple tyrosine kinase inhibitors block the “grow” signal in specific types of tumors. This policy discusses when multiple receptor tyrosine kinase inhibitors may be considered medically necessary. Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab.
    [Show full text]